NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy

Novartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.

Original reporting
Published Sep 8, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 8, 2026, 8:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy — source image
Decision brief

The 30-second read

$NVSBearishHigh
01

Why it matters

The failure triggered a sharp sell‑off in Novartis and pressured peer companies in the same therapeutic area.

02

Market read

Primary biotech news with immediate price impact; relevant for traders focused on pharma/biotech equities.

03

What to watch

Novartis still reports activity on secondary endpoints and maintains its longer‑term outlook, which could cushion the fallout.

Relevance 8/10Novelty 9/10Timing: same-day Tuesday

Background

Novartis announced a Phase 3 trial failure for del‑desiran in myotonic dystrophy type 1, marking its second miss in a week after a heart‑drug trial.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis (NVS) reported its Phase 3 HARBOR trial failed primary endpoint, causing a 14% drop, its worst day in 20+ years.

Expected impact

Expect further downside pressure; potential short‑term sell‑off.

Evidence & confidence

Large‑cap biotech trial miss with double‑digit move; market reaction already strong.

$DYNBearishMedium confidence
Context

Dyne Therapeutics (DYN) shares fell 16% as investors reacted to Novartis' trial miss in the same disease area.

Expected impact

Likely continued weakness pending own data release.

Evidence & confidence

Peer failure creates sector pressure; no new data from DYN itself.

$SRPTBearishMedium confidence
Context

Sarepta Therapeutics (SRPT) dropped 7% following the same Novartis trial failure, affecting its DM1 pipeline perception.

Expected impact

Potential further decline until company clarifies its own pipeline.

Evidence & confidence

Peer disappointment influences investor sentiment; no direct news from SRPT.

Market effects

DM1 and rare‑disease biotech sector faces heightened risk perception.

European and US biotech indices may see modest pullback.

Limited to biotech niche; broader market largely unaffected.

Counterpoint

Some investors may view the sell‑off as an overreaction and look for a buying opportunity on the dip.

Key entities

  • Novartis

    Swiss pharma giant, ticker NVS.

  • Dyne Therapeutics

    Biotech developing zbasivarsen for DM1, ticker DYN.

  • Sarepta Therapeutics

    Biotech with SRP‑1003 program for DM1, ticker SRPT.

Related articles

$NVSMed

Novartis wins FDA approval for Cosentyx in polymyalgia rheumatica

Novartis announced FDA approval for Cosentyx (secukinumab) to treat polymyalgia rheumatica in adults unresponsive to corticosteroids. The 150-mg dose showed 40.5% remission at Week 52 vs. 20.5% for placebo. This is Cosentyx's 11th U.S. indication. The approval follows positive Phase III trial results, with the drug demonstrating steroid-sparing effects. Novartis also noted ongoing regulatory reviews in other regions.

$NVSMed

Novartis Pharma AG: Novartis Cosentyx becomes first and only FDA-approved anti-IL-17 biologic for people with polymyalgia rheumatica (PMR)

Novartis' Cosentyx (secukinumab) received FDA approval for treating polymyalgia rheumatica (PMR), marking its 11th US indication. The approval follows a Phase III trial where Cosentyx doubled sustained remission rates compared to placebo. Novartis aims to address the unmet needs of PMR patients, offering an alternative to long-term steroid use. The drug is already approved in the EU and under regulatory review in Japan.